Darmiyan has developed innovative technologies centered around their BrainSee software, which has received De Novo FDA approval. This software utilizes advanced medical imaging and artificial intelligence to assess brain health by analyzing the space between brain cells. By quantifying cellular-level changes within MRI scans, Darmiyan aims to provide early detection of neurodegenerative diseases, particularly Alzheimer's. Their approach combines over 40 years of neuroscience research with cutting-edge machine learning techniques, enabling the creation of non-invasive brain tests that are both accurate and accessible. The technology is designed to monitor patient-specific responses to interventions and facilitate drug development for Alzheimer's disease.

The core of Darmiyan's technology lies in its ability to generate detailed degeneration maps that highlight focal areas of brain degeneration. This capability not only aids in diagnosing conditions like mild cognitive impairment (MCI) but also offers prognostic insights that can guide treatment decisions. By focusing on high accuracy, non-invasiveness, and seamless integration into clinical practice, Darmiyan's solutions are positioned to transform the landscape of brain health monitoring and intervention. Their mission is to enhance the understanding and management of brain diseases, ultimately improving outcomes for patients and healthcare providers alike.

United States

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes.
Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

Darmiyan

Company Details